As shown in Figure 4, panel 3, a dose reduction to 300‐mg aripiprazole AOM for chronic coadministration of CYP2D6 or CYP3A4 inhibitors12 and a dose reduction to 200‐mg aripiprazole AOM for chronic coadministration of both inhibitors12 (recommended dose adjustments based on simulations) is expected to result in median steady‐state concentrations remaining within the therapeutic window. This evidence concerns the gene CYP2D6 and infectious otitis media.